AbbVie Inc. is expected to report a strong Q1 2026 performance with revenues around $14.7 billion, marking an 8% increase year-on-year. The company's growth is primarily driven by its immunology segment, with products like Skyrizi and Rinvoq compensating for Humira's patent expiration. However, AbbVie faces long-term risks from patent cliffs expected in the 2030s. While oncology investments offer growth potential, they carry execution risks and limited pipeline diversification. Investors are advised to hold or buy AbbVie for its 3.3% dividend yield and steady revenue growth, but should closely monitor the company's long-term immunology strategy.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
